Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Evaluate's commercial intelligence on the pharmaceutical, biotechnology, and medical device industries is consistently referenced by leading business and industry publications such as the Financial Times, Wall Street Journal, and Nature.
Download our latest Media Kit for a forward-looking view of top companies, products, and more to support your editorial content.
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
In data again provided in partnership with life sciences market intelligence firm Evaluate Ltd, Pfizer ranked first in 2018 prescription drug revenue, totaling $45.3…
Evaluate Pharma has predicted sales of around $262 million for Aliqopa by 2022.
But though Narasimhan figures the company's inventory of 10 therapeutic areas is enough, it's also not too many, the CEO said. “I’m not looking to increase this number…